Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Zirabev (bevacizumab)
pCPA File Number:
21105
Negotiation Status:
Concluded with an LOI
Indication(s):
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2019-03-12
Negotiation Process Concluded:
2019-08-28